American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Investing

Is it safe to buy the Tempus AI stock dip now?

by admin April 9, 2025
April 9, 2025
Is it safe to buy the Tempus AI stock dip now?

Tempus AI stock price remains in a deep bear market as investors worry that the hype that drove it to a record high was ending. The TEM stock initially peaked at $91.40 in February, and has now plunged to a low of $37.2, meaning that it has dropped by 60%. So, is it safe to buy the dip or wait for it to fall further?

Why Tempus AI has plunged

Tempus AI is one of the top American companies in the artificial intelligence space. Its goal is to help all players in the medical industry to simplify their operations, boost innovation, reduce costs, and grow sales. 

The Tempus Platform comprises three key components, including Tempus Hub, Tempus Lens, and Tempus Lens. Tempus Hub is a platform that streamlines providers’ workflows and gives access to patient insights. 

Lens is a platform that helps researchers to find, access, and analyze multimodal data and uncover crucial insights. Next is a tool that helps providers deliver the next steps in a patient’s care data. 

Analysts believe that the medical industry is one of the best use cases for the artificial intelligence industry. It is primarily useful in research since large AI models can analyze vast data within minutes. 

AI technology is also useful in areas like diagnostics and treatment. It generates results like DNA, RNA, clinical imaging, clinical EMR, and epigenetics. 

Tempus AI business has grown rapidly in the past few years as more companies have embraced its technology. It is now used by some of the top companies in the healthcare industry like AstraZeneca, GlaxoSmithKline, BioNTech, Rain Oncology, and Kronos Bio.

TEM business is growing

The most recent results showed that Tempus AI business was growing. Its quarterly revenue rose by 35.8% YoY in the last quarter of 2024 to $200.7 million. Most of this revenue came from its genomics segment, which made over $120.4 million. The data and services segment rose to $80.2 million.

Most importantly, the company is making more strides to become profitable. Its gross profit rose by almost 50% to $122.1 million, while the net loss improved to $13 million, up from $50 million a quarter earlier. 

The annual revenue jumped by 30% to $693 million, with its genomics business making over $451.7 million. The data and service segment rose to $241 million.

Analysts are optimistic that the Tempus AI business will continue doing well this year. The average estimate is that its first quarter revenue will be $248.8 million. Its annual revenue will be $1.24 billion, followed by $1.55 billion next year. The company will break even next year. 

Analysts are highly bullish on the TEM stock, with the average estimate being $64.22, higher than the current $37.23.

Read more: Cathie Wood bets big on Tempus AI: Is it the next big thing in health-tech?

Tempus AI stock price analysis

TEM stock chart | Source: TradingView

The daily chart shows that the TEM share price has crashed in the past few weeks, moving from the year-to-date high of $91.40 to a low of $37.23. This price is along the ascending trendline that connects the lowest swing since June last year. 

The stock has moved below the 25-day moving average. It has also moved slightly below the bottom of the trading range at $37.5. The Relative Strength Index (RSI) also dropped below the middle line at 50.

Therefore, the stock will likely continue falling as sellers target the key target at $25, the strong pivot, and reverse at $25. In the future, however, Tempus AI stock price will likely bounce back, and possibly retest its all-time high.

The post Is it safe to buy the Tempus AI stock dip now? appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Lululemom stock faces a double whammy: $130 target in sight
next post
Nio stock price resilient to trade war, yet crash to $1.12 likely

Related Posts

WOA Proprietary Technology Successfully Adapted to Produce Pea...

July 9, 2024

AMC stock nears the make or break price:...

September 16, 2024

USD/SGD forms golden cross: Is Singapore dollar about...

December 26, 2024

Bitcoin Well Launches Cash Vouchers For Canadian Customers

April 17, 2024

How will US tariffs affect the TLT and...

February 2, 2025

Brian Leni: Gold Stocks Now the “Most Glaring”...

March 15, 2024

How is the Smart Money Investing in Mining...

February 17, 2024

Top 6 Lithium Stocks of 2024

July 20, 2024

XRP vs XLM: Which is a better crypto...

May 24, 2025

Nikkei 225 Index outlook ahead of the BoJ...

April 30, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Trump wants Apple to shift iPhone production from India to the US: here’s what it means

      May 18, 2025
    • Inflation outlook in 2025: what April’s soft data isn’t telling you

      May 18, 2025
    • Rich List 2025: UK billionaires decline for first time in years amid market turmoil

      May 18, 2025
    • Novo Nordisk CEO to step down as obesity drug competition intensifies

      May 18, 2025
    • Argentina’s black market for dollar falters as President Milei dismantles currency controls

      May 18, 2025

    Categories

    • Business (2,939)
    • Investing (2,425)
    • Latest News (1,990)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved